Osimertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
ESMO Open 2023 Mar 09;8(2)101183, LC Villaruz, X Wang, EM Bertino, L Gu, SJ Antonia, TF Burns, J Clarke, J Crawford, TL Evans, DM Friedland, GA Otterson, NE Ready, AJ Wozniak, TE StinchcombeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.